Medicines shortages and discontinuations
Medicine shortages and discontinuations can potentially compromise patient safety. Health professionals and services should consider risk reduction strategies during periods of medicines shortages and discontinuations.
The Medication Safety Standard requires health organisations to consider safety implications when there is a shortage or discontinuation of a medicine and implement strategies to reduce risk.
Some of these strategies can include conserving medicines and considering approved alternatives.
Where do I go to understand if a medicine is in short supply, discontinued or recalled?
The Therapeutic Goods Administration (TGA) is responsible for receiving and publishing reports on shortages and discontinuations of prescription and certain over-the-counter medicines, along with publishing alerts on product recalls.
When a medicine supply disruption poses a significant risk to safety and quality and requires a national response, we collaborate with the TGA and Australian states and territories to provide safety guidance.
Advice and resources for medicines supply disruptions
We have a range of resources that:
- have information about medicines supply disruptions
- outline the actions required to minimise risks
- provide guidance and tools to minimise risk, including conserving medicines.
Fact sheets, safety and strategy considerations
- Conserving medicines with a focus on medicines shortages
- Safety considerations during oxytocin injection supply disruption fact sheet
- Discontinuation of Protaphane® InnoLet®: Strategies and safety considerations
- Discontinuation of insulin products: Strategies and safety considerations
- Safety considerations during benzathine benzylpenicillin (Billin L-A) supply disruption
- Conservation strategies and safety considerations during intravenous (IV) fluids supply disruption - Fact sheet
- Antimicrobial Shortages
- Antibiotic shortages - Clinicians working in the Aboriginal and Torres Strait Islander health sector